Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort by Willis, Mark et al.
This is an Open Access document downloaded from ORCA, Cardiff University's institutional
repository: http://orca.cf.ac.uk/87147/
This is the author’s version of a work that was submitted to / accepted for publication.
Citation for final published version:
Willis, Mark, Harding, Katharine, Pickersgill, T., Wardle, Mark, Pearson, O., Scolding, N., Smee, J.
and Robertson, Neil 2016. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-
centre cohort. Multiple Sclerosis Journal 22 (9) , pp. 1215-1223. 10.1177/1352458515614092 file 
Publishers page: http://dx.doi.org/10.1177/1352458515614092
<http://dx.doi.org/10.1177/1352458515614092>
Please note: 
Changes made as a result of publishing processes such as copy-editing, formatting and page
numbers may not be reflected in this version. For the definitive version of this publication, please
refer to the published source. You are advised to consult the publisher’s version if you wish to cite
this paper.
This version is being made available in accordance with publisher policies. See 
http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications
made available in ORCA are retained by the copyright holders.
Alemtuzumab for multiple sclerosis: Long term 
Follow-up in a multi-centre cohort 
 
MD Willis, KE Harding, TP Pickersgill, M Wardle, OR Pearson, NJ Scolding, 
J Smee and NP Robertson 
 
Neil Robertson-Institute of Psychological Medicine and Clinical Neuroscience, Cardiff 
University, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN, UK. 
RobertsonNP@cardiff. ac.uk 
 
MD Willis, KE Harding, NP Robertson 
Institute of Psychological Medicine and Clinical Neuroscience, Cardiff 
University, University Hospital of Wales, UK/ Department of Neurology, University Hospital of Wales, 
UK 
 
TP Pickersgill,  M Wardle, J Smee - Department of Neurology, University Hospital of Wales, UK 
OR Pearson Department of Neurology, 
Morriston Hospital, UK 
 
NJ Scolding-Department of Neurology, Southmead Hospital, UK 
614092MSJ0010.1177/1352458515614092Multiple Sclerosis 
 
Abstract 
Background: Alemtuzumab has recently been approved for treatment of relapsing MS, but concerns 
remain about its use since long-term studies of adverse events remain limited. Furthermore, a clear 
understanding of its application and durability of effect in clinical practice has yet to evolve. 
Objectives: To investigate long-term efficacy and safety outcomes in a multicentre cohort of patients 
treated with alemtuzumab. 
Methods: Patients treated from 2000 and followed-up at three regional centres were identified. 
Baseline and prospective data were obtained and validated by clinical record review. 
Results: One hundred patients were identified with a mean follow-up of 6.1 years (range 1–13). Forty 
patients were retreated with at least one further treatment cycle. Annualized relapse rates fell from 2.1 
to 0.2 (p<0.0001) post-treatment and were sustained for up to eight years of follow-up. Mean change 
in EDSS score was +0.14. Forty-seven patients developed secondary autoimmunity. 
Conclusion: Observed reduction in relapse rates reflected those reported in clinical trials, but we 
were unable to corroborate previous observations of disability reversal. 40% of patients required 
additional treatment cycles. Autoimmune adverse events were common, occurring at a higher rate 
than previously reported, but were largely predictable, and could be managed effectively within a 
rigorous monitoring regime. 
 
Introduction 
The range of effective treatments for relapsing multiple sclerosis (MS) is rapidly expanding, leading to 
an ever greater choice for both patients and clinicians. Although the new disease-modifying therapies 
have undergone rigorous clinical trials before reaching the clinic, post-marketing surveillance and 
reporting will be essential in order to fully understand safety and efficacy, and in some cases have 
been key in modifying use in clinical practice. Alemtuzumab is a humanized monoclonal antibody 
which targets CD52, a 12 amino acid glycosylated glycosylphosphatidylinositol-linked protein 
expressed on the cell surface of lymphocytes, monocytes, macrophages, eosinophils and NK cells.1,2 
The anti-CD52 effect of alemtuzumab results in rapid and profound depletion of circulating 
lymphocytes following intravenous infusion, as a result of antibody-dependent cell-mediated 
cytotoxicity.3 However, CD52 is not expressed on haematopoietic precursors, so allowing beneficial 
immune reconstitution.4,5 Although exhibiting a degree of individual variability, the pattern of immune 
reconstitution is not thought to reliably predict disease activity.6–8 
 
Early open label studies demonstrated a marked reduction of relapse rates and slowing of disability 
accumulation when given early in the course of disease. 9–14 One subsequent phase II trial15 and 
two phase III trials,16,17 both against an active comparator, have confirmed this effect, and open 
label follow-up data for the phase II trial also demonstrates durability of effect over five years of follow-
up.18 Despite the clear beneficial effects of alemtuzumab on MS disease activity, there have been 
concerns regarding its side-effect profile, initially cited by the US Food and Drug Administration as a 
reason not to approve its use in the United States, although later revoked. In particular, secondary 
autoimmune disease (AID) is said to affect approximately 30% of patients, with the thyroid gland the 
most common target.19 Other serious, but less common, forms of AID include idiopathic 
thrombocytopaenic purpura (ITP), haemolytic anaemia, autoimmune neutropaenia and 
glomerulonephritis (Goodpasture’s syndrome).15–17,19 In addition, predictable adverse infusion 
related reactions, including headaches, rigors, pyrexia and rash, affect the majority of patients.20 
Because of these issues, long-term follow-up data from both controlled trials and open label studies 
will continue to be of value in informing patient selection, retreatment strategies and long-term 
surveillance protocols. 
 
Alemtuzumab has been used in selected centres in the UK since 2000 as a practical, alternative 
treatment for patients with early, aggressive disease with poor prognostic indicators, at a time when 
access to more effective treatments was limited, and therefore offers a unique opportunity to access 
long term follow- up data collected in routine clinical practice. Patients presenting with high relapse 
rates,21 together with poor prognostic features,22–24 were considered candidates for treatment. We 
present data of a ‘realworld’ experience of the use of alemtuzumab in MS across three UK MS 
centres, focusing on relapse rates, disability data, re-treatment rates and adverse events. 
 
Methods 
Patients and data collection 
Patients referred to and assessed in the neurology department at the University Hospital of Wales, 
Cardiff, were identified as candidates for treatment with alemtuzumab if they had a relapsing disease 
course and evidence of aggressive disease, characterized by a high relapse rate, active disease on 
cranial MR imaging, rapidly accumulating disability, early motor, cerebellar or cognitive dysfunction or 
combinations of these factors, and were considered to have poor prognosis. A smaller number of 
patients were treated locally at regional specialist neuroscience centres in Swansea and Bristol 
following regional network case-based discussions. Patients receiving alemtuzumab as part of 
externally sponsored clinical trials were excluded from analysis. 
 
Prior to treatment all patients had a normal blood count, thyroid function tests, routine blood indices 
and white cell immunophenotyping. At the time of treatment no patient had evidence of active 
infection, and treatment during relapse was avoided whenever possible. Consent for treatment was 
obtained and explanation of potential risks and benefits provided. 
 
Treatment regimen and adverse event monitoring 
Prior to 2006, patients received an initiation dose of 24–30 mg alemtuzumab intravenously per day for 
five days, with 1 g intravenous methylpredniso-lone given as pre-treatment on the first three days only 
in order to ameliorate the expected infusion reaction side-effects related to cytokine release.20 After 
2006, the daily dose of alemtuzumab was reduced to 12 mg. Routine top-up treatment was 
administered after 12 months, consisting of three daily doses of alemtuzumab with concurrent steroid 
pre-treatment. Additional courses were given as indicated after intervals of not less than 12 months, 
as a result of one or more of the following factors: (1) disabling clinical relapse; (2) evolving disability 
with or without objective change in EDSS;(3) the development of new or enhancing lesions on MRI 
performed 12 months or more after a prior treatment cycle. 
 
A monitoring programme for adverse autoimmune events included monthly full blood count and urea 
and electrolytes, in addition to thyroid function tests with anti-thyroperoxidase antibodies at least six-
monthly intervals. Urinalysis was performed when indicated or during concomitant illness. Additional 
tests for relevant AID-related antibodies were per-formed when appropriate. 
 
Data analysis 
Patients were identified from a regional clinical data-base,25 and a systematic review of notes was 
per-formed to validate the dataset. Data was collected on demographics, EDSS scores, relapses, 
adverse events and prior medication use in order for further analysis to be performed. Final data 
capture was performed on 23 April 2015. Retreatment rates, annualized relapse rates (ARR) pre- and 
post-treatment, disability out-comes, adverse events, including rates of AID, and outcomes of 
pregnancies were investigated. Six-month sustained accumulation (SAD) and reduction of disability 
(SRD) was calculated according to established definitions.26 
 
 
 
Results 
Demographics 
One hundred patients treated with alemtuzumab since 2000 were identified (female 67, male 33) with 
a total follow-up of 607 patient years. Ninety-seven patients had relapsing onset disease at the time of 
first treatment. Three patients were subsequently re-classified as secondary progressive disease with 
frequent relapses with the benefit of hindsight. Demographic characteristics of the cohort are 
summarized in Table 1. 
 
The majority of patients (79%) have been followed-up for between two and ten years, with a small 
pro-portion being followed-up for less than two (9%) and more than ten (12%) years, respectively. 
27% patients had been on at least one prior disease-modifying therapy (DMT). These included 
avonex (4), azathioprine (2), betaferon (5), copaxone (5), extavia (1), methotrexate (1), 
mycophenolate mofetil (2), natalizumab (3) and rebif (18). Of the three patients treated with 
natalizumab, two patients developed thyroid autoimmunity; another patient was subsequently 
diagnosed with haemolytic anaemia and ITP. Three patients commenced alternative DMTs a mean of 
3.4 years following first alemtuzumab infusion. Two patients from this cohort have died; one following 
an ischaemic stroke 6.9 years after initial treatment and the other patient eight years after the first 
treatment infusion from aspiration pneumonia. 
 
Retreatment rates 
The majority of patients (53%) underwent or were planned to complete the standard two cycles of 
treatment. 28% patients received three treatments, 11% four treatments and one patient five 
treatments. Seven patients received one treatment cycle only, with the commonest reasons being 
concerns related to monitoring adherence (n=2), development of precancerous comorbidity (n=1) or 
severe infusion reactions (n=3). One of the first patients to be treated also only received one cycle 
when experience of using alemtuzumab was more limited. Indications for 53 re-treatment cycles in 40 
patients are outlined in Table 2. Figure 1 demonstrates the temporal relationship between retreatment 
events and duration of follow-up. Between two and five years, 27% of patients had been retreated, 
increasing to 51% and 58% at five to ten years and greater than ten years follow-up, respectively. 
 
Relapses 
One hundred patients experienced a total of 766 relapses, of which 170 (22%) followed the initial 
treatment cycle. The mean pre-treatment annualized relapse rate (ARR) was 2.1 (median 1.8). 
Following the first treatment cycle the ARR reduced to 0.2 (median 0.1) (p<0.0001) (Figure 2). A 
small number of patients were unresponsive to treatment and continued to experience frequent 
clinical relapses: four patients had ⩾10 post treatment relapses and had a post treatment ARR of >1. 
The reduction in ARR was sustained over follow-up of up to eight years (Figure 3). 
 
Disability 
Mean baseline EDSS was 4.0. Mean change in EDSS from treatment baseline was +0.14. For two 
patients who died of non-MS related causes, the last EDSS recorded in life was selected as their final 
EDSS assessment. A negative change in EDSS was seen for each of the first three years of follow up, 
and then again towards the later years of follow up, although the numbers were small in these latter 
groups (Figure 4). 27% had a SAD, although none had developed this status within two years of 
follow-up. 25% of patients achieved sustained reduction in disability (SRD). Twelve patients (12%) 
were considered to have developed secondary progressive disease a mean of 3.8 years after initial 
treatment. 
 
 
 
 
Figure 1. Temporal variation in retreatment rates. Horizontal lines represent duration of follow-up. 
Treatments indicated by different symbols. 
 Adverse events 
Infusion reactions. 87% of patients experienced early infusion related adverse events, which 
occurred despite concomitant steroid use, but tended to be mild, and responded to conservative 
treatment. 
 
Acquired autoimmune disease. Fifty-one AID diagnoses were made in a total of 47 patients. As 
noted in previous studies, the thyroid gland was the most com-mon site of autoimmunity, with 35% 
patients affected. Three patients developed idiopathic thrombocytopaenic purpura (ITP) and 13 
other separate autoimmune disorders were diagnosed; one case each of haemolytic anaemia, 
pancytopaenia, autoimmune hepatitis, type II diabetes mellitus and anti-phospholipid syndrome, 
and two cases each of alopecia, neutropaenia, autoimmune alveolitis and vitiligo. Mean time to 
development of AID was 995 days (median 898, range 30–3180 days, Figure 5) following first 
treatment and a mean of 578 days (median 394, range 0–3180 days, supplementary figure 1) after 
the most recent treatment. The risk of developing secondary autoimmunity was greatest in the first 
five years of follow-up (Figure 5) and reduced after this time. No autoimmune kidney disease was 
observed in this cohort. In addition to the reported three cases of ITP, a transient infusion related 
thrombocytopaenia was observed in two patients, but resolved without intervention. 
 
A total of 34 different novel auto-antibodies (excluding thyroid receptor and anti-TPO antibodies) 
were detected in 30 different patients during the period of follow-up; 13 ANA, nine ANCA, three 
anti-smooth muscle antibodies, two anti-centromere antibodies, two parietal cell antibodies, one 
rheumatoid factor, one anti-dsDNA, one anti-cardiolipin, one Beta 2 Glycoprotein 1 antibody and 
one anti-GBM antibody. Importantly, the patient who developed anti-GBM antibodies had normal 
renal function throughout the course of treatment. The majority of these detected auto-antibodies 
were transient, with only four anti-bodies persisting after subsequent testing. These included one 
anti-centromere antibody, two ANCA and one anti-cardiolipin antibody. 
 
Figure 2. Pre- and post-treatment relapses for patients treated with alemtuzumab. 
 Infections. Forty-two documented infections occurred in 23 patients. All infections were mild or 
moderate in severity and responded to standard treatment. Urinary tract infections were most 
common (12%). Eight  (8%) patients developed herpes zoster and six (6%) respiratory tract 
infections. Other diagnoses were less common, and included influenza (3%) pityriasis (2%), sinusitis 
(2%), tonsillitis (2%), genital herpes simplex (1%), conjunctivitis (1%), mastitis (1%), mumps (1%), 
acute cholangitis (1%) and cellulitis (1%). One patient (1%) developed cryptosporidium infection 
during a hospital in-patient stay for a surgical operation. 
 
 
 
Figure 3. Annualized relapse rate by year of follow-up. 
 
 
Figure 5. Risk of developing autoimmune disease by duration of follow-up. Lined columns: thyroid 
autoimmune disease; grey columns: idiopathic thrombocytopaenic purpura; black columns: other 
autoimmune conditions. 
 
Pre-malignant/malignant conditions. Ten patients developed pre-malignant or malignant conditions 
during the period of follow-up. Five patients (5%) developed cervical dysplasia, three patients (3%) 
were identified with a low level IgG paraprotein or monoclonal gammopathy of uncertain 
significance (one of which was also diagnosed with meningioma) and two patients were diagnosed 
with basal cell carcinoma. 
 
Pregnancy. Thirteen pregnancies were recorded in twelve women (18%). Two pregnancies resulted 
in miscarriage and one was terminated. The child of one patient who developed thyroid AID 
following treatment experienced transient neonatal hyperthyroidism. 
 
Discussion 
Alemtuzumab has had encouraging results in both clinical trials and open-label studies, but long-
term follow up data remains sparse. Tuohy et al.26 have recently published long term results of a 
cohort of patients treated in open-label studies in Cambridge, UK, but additional data from other 
centres is also required tounderstand practical application and longer-term adverse events in 
routine clinical practice. 
 
In the phase II (CAMMS223) and phase III trials (CARE-MSI and CARE-MSII), alemtuzumab was shown 
to reduce the ARR by 74%, 55% and 49.4%, respectively. The findings in this study confirm that up to 
a mean 6.1 year follow-up the percentage reduction in ARR is maintained, and in this cohort was 
90%. In particular, the treatment seems to be durable in relation to relapses up to eight years 
following treatment. After this time the ARR reduces, but the number of patients in this group is 
small. Four patients clearly did not respond to treatment, with ⩾10 post-treatment relapses and a 
combined post-treatment ARR of >1, and represent an interesting sub-group which may warrant 
more detailed analysis of disease biology. Further characteristics of this subgroup are detailed in 
Table 1. However these data are commensurate with the long-term efficacy outcomes of the 
Cambridge cohort, where 52% received the standard two cycles of treatment, 36% received three 
cycles, 8% four cycles and one patient five cycles.26 In our dataset the trend for requiring re-
treatment increased over time, implying that the majority of patients are likely to require further 
treatment cycles. So far 40% of patients have required retreatment. An important practical 
consideration was that significant cognitive deficits were identified as a barrier to informed consent 
and adherence to long term monitoring protocols, and we have now altered our local selection 
criteria to offer alternative treatments for these patients. Three (3%) patients were also intolerant of 
treatment as a result of severe infusion reactions or pancytopaenia following infusion. 
 
Previous studies have suggested an expectation of  an improvement in EDSS from baseline following 
treatment with alemtuzumab when compared with  an active comparator (interferon beta 1-a). In 
the CAMMS223 phase II study, the mean change in EDSS from baseline was −0.39 (p<0.001),15 
CARE-MSI 0.14 (p=0.97),16 CARE-MSII −0.17 (p<0.0001)17 and CAMMS223 five-year follow-up −0.3 
(p=0.0002).27 Although the improvement in EDSS in the CAMMS223 cohort achieved statistical 
significance over five years of follow-up, this significance was not observed when months 36–60 only 
were analysed. This would imply that the proposed effect on disability was short-lived and not 
sustained. Conversely, our cohort experienced an overall worsening in EDSS score of +0.14 from 
treatment baseline. The previous phase II and two phase III trials have shown rates of SAD in the 
alemtuzumab treatment groups of 9%, 8% and 13% at three, three, and two years, respectively. 
Similarly, 11% of patients had SAD in the CAMMS223 five-year follow-up study. We identified a 
much higher proportion of patients who had SAD over six years follow-up, so that 27% of patients 
were deemed to have progressed in our cohort. These results, however, were comparable to the 
levels of SAD found in the open-label Cambridge long-term follow-up study, with 32% of patients 
found to have SAD over a median seven-year follow-up.26 Only 27% of patients had a SRD in our 
cohort, compared to 43.5% in the Cambridge cohort.26 Differences in disability outcomes may, in 
part, be explained by the fact that in our cohort there were a larger number of EDSS assessors, as 
would be expected in a ‘real-world’ clinical setting, but this may have created some increased 
variability. Although the mean change in EDSS score was +0.14, we would still consider this an 
encouraging outcome, given the particularly aggressive disease profile of this cohort of patients. 
 
The most significant adverse event of alemtuzumab treatment is secondary AID. Secondary thyroid 
auto-immunity has previously been shown to be unaffected by the cumulative dose, dosage interval 
or dosage frequency, suggesting that total risk is acquired at the time of first dose.28 47% of patients 
in this study developed AID, with 35% developing thyroid autoim-munity.10,12,15–17,28 Rates of 
ITP (3%) were also com-parable to published data. Other AIDs were seen at lower frequencies, but 
without a control group for comparison, the relationship of these to alemtuzumab treatment is 
difficult to confirm. This risk of developing secondary AID appears to be maximum in the first five 
years following initial treatment, with only three cases (all thyroid AID) seen after this time. This 
would seem to suggest that autoimmune surveillance should be continued for a minimum of five 
years after the first treatment cycle. This is commensurate with the current monitoring guidelines of 
four years after the last dose of alemtuzumab. Although 34 novel anti-bodies were detected during 
post-treatment monitoring only four of these persisted, and have not so far been associated with 
relevant disease. 
 
Despite alemtuzumab causing profound and prolonged lymphopaenia, serious infections are rare. 
This is thought to be due to the relative preservation of the innate immune system, haemopoetic 
stem cells and the nature of subsequent immune reconstitution.4 In addition, as a result of the 
interval between treatments, lymphocyte repopulation occurs. Most infections following 
alemtuzumab treatment are mild to moderate and respond to conventional therapies. We observed 
similar findings in this study, with urinary, respiratory and herpes zoster infections being most 
common. One case of cryptosporidium infection was associated with an in-patient stay for a surgical 
procedure. We are unaware of any serious infections occur-ring in our cohort. 
 
Within the clinical trials, the rate of pre-malignant or malignant conditions was 0.5%–2.8%, although 
the studies were not powered in such a way as to detect small changes as compared with interferon 
beta-1a. Outside of trials one case of malignant melanoma  has been reported,29 and a further 
patient developed Castleman’s disease (a prelymphomatous condition) and is now in remission 
following R-CHOP chemo-therapy.30 We observed pre-malignant/malignant conditions in 10% of 
patients. In particular, we are aware of five female patients who developed cervical dysplasia (5%). 
The occurrence of cervical dysplasia may be affected by immunosupression,31 and these data 
perhaps suggest that stringent pre- and post-treatment cervical screening should be performed, and 
this is now included as routine in our protocols. In addition to these findings, an IgG paraprotein or 
MGUS was also detected on screening in three patients. The significance of this is difficult to 
ascertain at present, but is a novel finding in MS patients receiving alemtuzumab, although 
persistent paraproteinaemias have previously been reported following alemtuzumab therapy in the 
context of stem cell transplantation.32 
 
The pregnancy rate of 18% in this cohort, despite advice on appropriate contraception, may reflect 
the positive effect on quality of life following alemtuzumab that many patients reported, leaving 
them more confident to start families. No unexpected adverse pregnancy outcomes have so far been 
observed in this cohort. 
 
In conclusion, this follow-up study in a highly selected group of MS patients with poor prognostic 
indicators, treated with alemtuzumab in routine clinical practice, confirms a durable effect on 
relapse rates, but no improvement in disability. AID has affected nearly half of the cohort to date, 
but this figure is likely to rise with longer follow-up. Unexpected findings included three cases of a 
low level IgG paraprotein and five cases of cervical dysplasia. Although the lack of a comparative 
control group does not allow definitive conclusions to be drawn, it will be important to monitor 
these in larger post-marketing surveillance studies. However, alemtuzumab appears to be an 
effective treatment for relapsing MS in routine clinical practice, and its side-effects, for the most 
part, are predictable and treatable. 
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